6vrp: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Reverse Transcriptase Diabody with R83T Mutation== | ==Reverse Transcriptase Diabody with R83T Mutation== | ||
<StructureSection load='6vrp' size='340' side='right'caption='[[6vrp]]' scene=''> | <StructureSection load='6vrp' size='340' side='right'caption='[[6vrp]], [[Resolution|resolution]] 1.60Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6VRP OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6VRP FirstGlance]. <br> | <table><tr><td colspan='2'>[[6vrp]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6VRP OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6VRP FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6vrp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6vrp OCA], [https://pdbe.org/6vrp PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6vrp RCSB], [https://www.ebi.ac.uk/pdbsum/6vrp PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6vrp ProSAT]</span></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6vrp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6vrp OCA], [https://pdbe.org/6vrp PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6vrp RCSB], [https://www.ebi.ac.uk/pdbsum/6vrp PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6vrp ProSAT]</span></td></tr> | |||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
This work presents a method for introducing synthetic symmetry into protein crystallization samples using an antibody fragment termed a diabody (Dab). These Dabs contain two target binding sites, and engineered disulfide bonds have been included to modulate Dab flexibility. The impacts of Dab engineering have been observed through assessment of thermal stability, small-angle X-ray scattering, and high-resolution crystal structures. Complexes between the engineered Dabs and HIV-1 reverse transcriptase (RT) bound to a high-affinity DNA aptamer were also generated to explore the capacity of engineered Dabs to enable the crystallization of bound target proteins. This strategy increased the crystallization hit frequency obtained for RT-aptamer, and the structure of a Dab-RT-aptamer complex was determined to 3.0-A resolution. Introduction of synthetic symmetry using a Dab could be a broadly applicable strategy, especially when monoclonal antibodies for a target have previously been identified. | |||
Co-crystallization with diabodies: a case study for the introduction of synthetic symmetry.,Chesterman C, Arnold E Structure. 2021 Feb 23. pii: S0969-2126(21)00045-9. doi:, 10.1016/j.str.2021.02.001. PMID:33636101<ref>PMID:33636101</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 6vrp" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Human]] | |||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Arnold E]] | [[Category: Arnold, E]] | ||
[[Category: Chesterman C]] | [[Category: Chesterman, C]] | ||
[[Category: Diabody]] | |||
[[Category: Immunoglobin]] | |||
[[Category: Protein binding]] | |||
[[Category: Reverse transcriptase]] | |||
Revision as of 20:50, 10 March 2021
Reverse Transcriptase Diabody with R83T MutationReverse Transcriptase Diabody with R83T Mutation
Structural highlights
Publication Abstract from PubMedThis work presents a method for introducing synthetic symmetry into protein crystallization samples using an antibody fragment termed a diabody (Dab). These Dabs contain two target binding sites, and engineered disulfide bonds have been included to modulate Dab flexibility. The impacts of Dab engineering have been observed through assessment of thermal stability, small-angle X-ray scattering, and high-resolution crystal structures. Complexes between the engineered Dabs and HIV-1 reverse transcriptase (RT) bound to a high-affinity DNA aptamer were also generated to explore the capacity of engineered Dabs to enable the crystallization of bound target proteins. This strategy increased the crystallization hit frequency obtained for RT-aptamer, and the structure of a Dab-RT-aptamer complex was determined to 3.0-A resolution. Introduction of synthetic symmetry using a Dab could be a broadly applicable strategy, especially when monoclonal antibodies for a target have previously been identified. Co-crystallization with diabodies: a case study for the introduction of synthetic symmetry.,Chesterman C, Arnold E Structure. 2021 Feb 23. pii: S0969-2126(21)00045-9. doi:, 10.1016/j.str.2021.02.001. PMID:33636101[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||